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Novel p19 Protein Engages IL-12p40 to Form
a Cytokine, IL-23, with Biological Activities
Similar as Well as Distinct from IL-12
ducing chains. The presence of shared signal-transduc-
ing receptors offers an explanation for the overlapping
functions of IL-6-like cytokines.
Two other IL-6-like cytokines, G-CSF and the p35
subunit of IL-12, signal through private superfamily re-
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DNAX Research Institute with a chain known as p40 (Kobayashi et al., 1989).
Whereas p35 shows homology to the IL-6-type cyto-Palo Alto, California 94304
kines and G-CSF, p40 is a soluble member of the cyto-
kine receptor superfamily. Only the composite p35p40
IL-12 molecule was found to display biological activity,Summary
although a p40 homodimer may function as an IL-12
antagonist by competing for the IL-12 receptor (GatelyA novel sequence discovered in a computational
et al., 1996).screen appears distantly related to the p35 subunit
IL-12 plays a critical role in cell-mediated immunityof IL-12. This factor, which we term p19, shows no
(Gately et al., 1998; Trinchieri, 1995, 1998). Its activitiesbiological activity by itself; instead, it combines with
are triggered through a high-affinity receptor complexthe p40 subunit of IL-12 to form a novel, biologically
that gathers two closely related subunits, IL-12Rb1 andactive, composite cytokine, which we term IL-23. Acti-
b2 (Chua et al., 1995; Presky et al., 1996b). Although novated dendritic cells secrete detectable levels of this
evidence exists for IL-12 receptor promiscuity, the p35complex. IL-23 binds to IL-12Rb1 but fails to engage
subunit has been suggested to bind to a second solubleIL-12Rb2; nonetheless, IL-23 activates Stat4 in PHA
cytokine receptor called EBI3 (Devergne et al., 1997).blast T cells. IL-23 induces strong proliferation of
However, no biological activity has been reported formouse memory (CD41CD45Rblow) T cells, a unique ac-
the p35-EBI3 pair. By contrast, phenotypic differencestivity of IL-23 as IL-12 has no effect on this cell popula-
between IL-12 p40-deficient mice and IL-12 p35-defi-tion. Similar to IL-12, human IL-23 stimulates IFN-g
cient mice with respect to the clearance of bacterialproduction and proliferation in PHA blast T cells, as
infections (Decken et al., 1998; Brombacher et al., 1999)well as in CD45RO (memory) T cells.
invite the possibility that p40 is involved in functional
complexes with molecules other than p35.Introduction
In this report, we describe a novel helical cytokine
that was identified by searching sequence databasesThe proliferation, differentiation, and effector functions
with a computationally derived profile of IL-6 subfamilyof immune cells are regulated in part by a network of
structures. This protein was designated p19, represent-soluble protein factors. Discrete families of these mole-
ing its approximate molecular weight. We further showcules have been identified by sequence and structural
that p19 is part of a novel composite factor that consistsanalysis. Within the diverse set of sampled protein folds,
of a disulfide-bridged complex between p19 and the p40the four–a helix bundle topology uniquely distinguishes
subunit of IL-12. This novel p19p40 complex is naturallymembers of the hematopoietic cytokine family (Rozwar-
expressed by activated mouse and human dendriticski et al., 1994). Among the members of this large family,
cells and has biological activities that are similar to buta further clustering is evident. Within these subfamilies,
distinct from IL-12. These activities result from interac-members often display faint but significant stretches
tion of the p19p40 complex with IL-12Rb1 and an addi-of amino acid similarity that are indicative of a closer
tional, novel receptor subunit.evolutionary and functional relationship.
A particularly important subfamily of helical cytokines
encompasses a set of factors that are related to interleu- Results
kin-6 (IL-6). These now include IL-11, leukemia inhibitory
factor (LIF), oncostatin M (OSM), cardiotrophin-1 (CT-1), p19 Was Identified Computationally
We searched sequence databases with a computation-ciliary neurotrophic factor (CNTF), and novel-neuro-
trophin-1 (NNT-1). This group of cytokines exhibits a ally derived profile (Gribskov et al., 1987) of members
of the interleukin-6 (IL-6) helical cytokine family. Thiswide range of often overlapping biological functions that
are transmitted via multichain cell surface receptors, search led to identification of a novel cytokine, which
we named p19. The p19 cDNA sequences encode 189/196which are typically formed by high-affinity, cytokine-
specific receptor chains and lower-affinity, signal-trans- amino acid polypeptides (human and mouse, respec-
tively) corresponding to mature proteins with calculated
molecular weights of 18.7 and 19.8 kDa. Both proteins* To whom correspondence should be addressed (e-mail: kastelein@
contain five cysteine residues and no N-glycosylationdnax.org).
† These authors contributed equally to this work. sites. Human and mouse p19 are 70% identical and most
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Figure 1. Alignment of Amino Acid Sequences for Selected Members of the Long Chain a-Helical Cytokine Family
(A) Sequences for all cytokines are shown as mature peptides (human p35, GenBank accession number B38957; mouse p35, NP_032377;
human IL-6, P05231; mouse IL-6, P08505; human G-CSF, NP_000750; and mouse G-CSF, NP_034101). The alignment is based on the
overlapping structures of IL-6 (PDB entry code 1il6) and G-CSF (PDB entry code 1rhg). The a helices of hIL-6 and hG-CSF are boxed according
to their secondary structures. The four helices predicted for p19 and p35 are labeled A, B, C, and D. The two disulfide bonds in IL-6 and
G-CSF are numbered 1 and 2. Closed triangle indicates the position of 25 additional amino acids in human and mouse p35, not shown in the
alignment, but that likely pack against the helix bundle. The amino acid coloring scheme depicts chemically similar residues: green (hydropho-
bic), red (acidic), blue (basic), yellow (C), orange (aromatic), black (structure breaking), and gray (small).
(B) Evolutionary dendrogram of selected cytokines, showing the branching pattern that captures the various IL-6-like subgroups. The tree is
rooted by leptin.
closely related to IL-12p35, IL-6, and G-CSF (Figure 1A). (Figure 2A, lane 2) could be immunoprecipitated from
the supernatant. Both proteins could be detected in theAn evolutionary dendrogram shows p19 and IL-12p35
as closest neighbors (Figure 1B). cellular lysates of transfected cells, indicating inefficient
secretion (data not shown). mp19 transfection superna-
tant or semipurified mp19 protein was inactive when
p19 and IL-12p40 Form a Novel Composite Factor analyzed in various bioassays (data not shown). We next
The presence of a signal peptide suggested that p19 investigated the possibility that p19 is part of a compos-
would be secreted when expressed in mammalian cells. ite factor like IL-12 (Gubler et al., 1991; Wolf et al., 1991)
However, upon transfection of 293T cells with tagged and requires coexpression with a partner protein to be
forms of human or mouse p19, only a small amount of efficiently secreted. p19 was coexpressed with various
nonsignaling receptors of the IL-6 family, includingmouse (Figure 2B, lane 2) but not the human protein
Novel Composite Factor p19p40 Is Related to IL-12
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Figure 2. IL-12p40 and p19 Form a Soluble
Disulfide-Linked Heterodimer
(A and B) 293T cells were transiently trans-
fected with empty vector (lanes 1 and 5) or
expression vectors for p19-Flag (lanes 2 and
6), IL-12 p40 (lanes 3 and 7), or both (lanes 4
and 8). Twenty-four hours after transfection,
cells were metabolically labeled for 16 hr, and
proteins were immunoprecipitated from su-
pernatant with anti-Flag agarose or p40-spe-
cific antibodies coupled to protein G sepha-
rose. Immunoprecipitation of the human (A)
and the mouse (B) p19p40 complex.
(C and D) Nonreduced followed by reduced
SDS-PAGE on mouse p19p40 supernatant
purified from adenovirus coinfected 293T
cells by heparin chromatography. (C) Silver
stained gel. (D) Anti-mp19 Western blot. Mo-
lecular weight markers are indicated in kDa.
tagged forms of EBI3, soluble IL-6R, NR6 (CLF-1), and human dendritic cells derived from peripheral blood ad-
herent cells were stimulated with GM-CSF and IL-4 forIL-12p40. Among these molecules, only the coexpres-
sion of p19 and IL-12p40 led to enhanced secretion of 5 days. After culture with TNFa, LPS, and anti-CD40
antibody for 2 days, the culture supernatant was har-p19 (Figure 2, lanes 4 and 8). Moreover, both proteins
were coimmunoprecipitated with antibodies against ei- vested. A native mouse p19p40 complex could be de-
tected in a sandwich ELISA (Figure 4A) as well as byther tagged p19 or p40 (anti-Flag or anti-p40, respec-
tively), indicating that p19 and IL-12p40 form a soluble SDS-PAGE/anti-mp19 Western blot (Figure 4B). Simi-
larly, a native human p19p40 complex was immunopre-cytokine/receptor complex similar to that of IL-12
p35p40. A small amount of mp19 migrates at a slightly cipitated from activated human DC with anti-hp40 mAb.
The precipitate was resolved on IEF/SDS-PAGE 2D gelshigher molecular weight (Figure 2B). The higher band
could result from O-linked glycosylation. Several poten- (Figure 4D) and compared to the patterns obtained with
similar precipitates from specific 293T cell cotransfec-tial O-linked glycosylation sites are predicted (Hansen et
al., 1998). To investigate whether p19p40 is a disulfide- tion experiments (Figure 4C).
linked heterodimer like IL-12, the complex was purified
from adenovirus p19 and p40 coinfected 293 cells and p19p40 Specifically Acts on Mouse Memory T Cells
analyzed on two-dimensional SDS gels. Silver staining To investigate the biological effects of the p19p40 com-
of the gel showed the presence of p19p40 disulfide- plex, we initially engineered a soluble tagged fusion pro-
linked heterodimer in addition to free p40 monomers tein by flexibly linking the mouse p40 chain to mouse
and dimers (Figure 2C). The identity of the mouse p19 p19 (Hy-p40-p19). This chimeric molecule follows the
spot on the silver stained gel was confirmed by anti- design of the “hyper-IL-6” cytokine (IL-6Ra-IL-6, (Fi-
mp19 Western blot (Figure 2D). scher et al., 1997) that shows greater solution stability,
presumably because the cytokine and its cognate re-
ceptor domains are closely tethered and form a compos-Natural p19p40 Is Expressed by Activated
Dendritic Cells ite binding surface for the cellular receptors. A similar
p40-p35 fusion protein shows specific activity identicalExpression analysis of mouse cDNA libraries showed
the presence of p19 mRNA in various tissues and cell to native IL-12 (Anderson et al., 1997). For our biological
studies, we have used both mouse and human Hy-p40-types (Figure 3A). Highest mRNA levels were found in
polarized Th1 cells and activated macrophages. We p19 proteins. Experiments were also performed with
conditioned medium of p19p40 cotransfected cells orcould not detect p19 mRNA in bone marrow–derived
dendritic cells. In contrast, both mouse and human den- adeno coinfected cells with identical results. First, we
investigated the role of the Hy-p40-p19 on CD41 Tdritic cells derived from peripheral blood monocytes
express high levels of p19 mRNA (Figure 3B). Monocyte- cell subsets in comparison to IL-12. Naive T cells
(CD41CD45RBhigh) and memory/activated T cellsderived dendritic cells cultured in GM-CSF and IL-4 and
activated via CD40 for 2 days also express high levels (CD41CD45RBlow) were sorted from IL-10-deficient mice,
which have elevated levels of memory T cells comparedof p40 mRNA and to a lesser extent p35 mRNA (Figure
3B). We analyzed natural p19p40 in the supernatants of to wild-type mice (Davidson et al., 2000). The T cell
subsets were stimulated with anti-CD3 mAb for 5 daysactivated mouse and human dendritic cells. Mouse and
Immunity
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Figure 4. Natural p19p40 Heterodimer in Activated Mouse and Hu-
man Dendritic Cell Supernatants
DC supernatants and control medium were concentrated prior to
detection by ELISA or immunoprecipitation (IP).
(A) Sandwich ELISA on activated (open circles) and immature
(closed circles) mouse DC supernatant. Medium (open squares),
1000 ng/ml IL-12 (open diamonds), and 100 ng/ml Hy-p40-p19
(closed squares) were used as controls. Plates were coated with
mp19-specific mAb 20C10. Bound cytokine was detected with bio-
tinylated anti-mp40 mAb and HRP-streptavidin.
(B) Detection of mouse DC-produced p19 by Western blot. Control
medium and DC supernatant were treated with rat anti-mp40 and
isotype control beads, respectively. Blotted protein was detected
with rat anti-mp19 mAb 10A11 and HRP-conjugated anti-rat an-
tibody.
(C) IEF/SDS-PAGE 2D gels of human IL-12 p35p40 (left) and p19p40
(right) from 293T cotransfected cells.
(D) Human immature (left) and activated (right) dendritic cell super-
natants.
in the presence of anti-IL-2 mAb and various amounts
of IL-12 or Hy-p40-p19. Upon stimulation in the presence
of IL-12, naive (CD41CD45RBhigh) but not memory T cells
Figure 3. Distribution of Mouse p19, IL-12p35, and IL-12p40 mRNA (CD41CD45RBlow) proliferated (Figure 5A). In contrast,
in Various Tissues and Cell Types
Hy-p40-p19 protein had no effect on naive T cells but
(A) Quantitative PCR on various mouse libraries. (B) Quantitative
strongly induced proliferation of memory T cells. ThePCR on human cultured dendritic cells. Dendritic cells were derived
stimulatory effect on the memory T cells was 100-foldfrom human monocytes cultured in GM-CSF and IL-4 for 6 days
lower in the presence of a neutralizing anti-IL-12p40and activated for 2 days in coculture with CD40L transfected L cells.
Total RNA was isolated and analyzed for expression of p19, IL- antibody. The same proliferative signal could be induced
12p40, and IL-12p35 mRNA by using the Taqman technique. mRNA by stimulation with conditioned medium of p19p40 co-
levels are expressed in fg per 50 ng of cDNA. transfected cells (Figure 5B). Similar results were ob-
tained with memory T cells from wild-type mice; how-
ever, their response to Hy-p40-p19 was always less than
Novel Composite Factor p19p40 Is Related to IL-12
719
Figure 5. p19p40 Stimulates the Proliferation
of Mouse Activated/Memory T Cells but Not
Naive T Cells
(A) Sorted CD41CD45RBhigh or CD41
CD45RBlow T cells were cultured with plate-
bound anti-CD3 mAb. Anti-IL-2 mAb (100 mg/
ml) was added to all cell cultures. Mouse IL-
12 or purified mouse Hy-p40-p19 was titrated
into the cultures, 6 anti-IL-12(p40) mAb (250
mg/ml). [3H]TdR incorporation (counts per mi-
nute) was assessed after 5 days of culture.
Data are mean 6 SD of triplicate wells and
are representative of three experiments.
(B) Sorted CD41CD45RBlow similarly treated.
Purified mouse Hy-p40-p19 (started at 500
ng/ml) or supernatant from 293T cells cotrans-
fected with p19 and p40 (started at 5% by
volume) was titrated into the culture, 6 anti-
IL-12(p40) mAb (250 mg/ml). [3H]TdR incorpo-
ration (counts per minute) was assessed after
5 days of culture. Data are mean 6 SD of
triplicate wells.
the response of T cells from IL-10-deficient mice (data vated CD45RA T cells did not produce IFN-g in the ab-
sence of Hy-p40-p19 or IL-12, whereas CD45RO T cellsnot shown).
produced moderate amounts at day 3 and day 6 (Figure
6C). Addition of Hy-p40-p19 to these cultures did notp19p40 Acts on Human Memory and Naive T Cells
We next analyzed the ability of human Hy-p40-p19 to enhance IFN-g production by CD45RA T cells at 3 days
after activation but caused a modest increase in IFN-ginduce proliferation and IFN-g production in human PHA
blast T cells. Hy-p40-p19 significantly enhanced the pro- production at day 6. In contrast, Hy-p40-p19 enhanced
IFN-g production by CD45RO T cells at both day 3 andduction of IFN-g by 7-day-old PHA blasts activated by
plate-bound anti-CD3 and soluble anti-CD28 mAbs (Fig- day 6 after activation. Addition of IL-12 slightly enhanced
production of IFN-g by CD45RA T cells at day 3 buture 6A). The maximal levels of IFN-g production induced
by saturating amounts of Hy-p40-p19 were lower com- induced a significant increase at day 6, which is in agree-
ment with the previously described requirement forpared to those induced by saturating amounts of IL-12.
The IFN-g enhancing effects of both Hy-p40-p19 and upregulation of IL-12Rb2 expression on naive T cells
(Rogge et al., 1997). In addition, IL-12 significantly en-IL-12 could be blocked by anti-IL-12Rb1 or anti-p40/
p70 antibodies. However, the anti-p35 antibody only hanced the production of IFN-g by CD45RO T cells at
both day 3 and day 6. Expression of IFN-g was in allblocked the IFN-g production induced by IL-12 and not
that induced by Hy-p40-p19. The low level IL-4 produc- cases strongly dependent on the endogenous produc-
tion of IL-2 since neutralization with anti-IL-2 and anti-tion by PHA blasts was not affected by Hy-p40-p19 or
IL-12 (data not shown). Hy-p40-p19 and IL-12 enhanced IL-2Ra mAbs abolished it completely (data not shown).
Neither Hy-p40-p19 nor IL-12 induced IFN-g productionthe proliferation of PHA blasts (Figure 6B). Again, the
effects of Hy-p40-p19 on proliferation could be blocked by CD45RA or CD45RO T cells in the absence of activa-
tion by anti-CD3 and anti-CD28 mAbs (data not shown).by anti-IL-12Rb1 or anti-p40/p70 but not by anti-p35
antibodies. Similar to the experiments in the mouse, Hy-p40-p19
induced a more pronounced effect on proliferation ofWe also compared the activity of Hy-p40-p19 and IL-
12 on CD45RA (naive) and CD45RO (memory) T cell CD45RO T cells as compared to CD45RA T cells at day
6 after activation in the absence of endogenous IL-2populations isolated from PBMC. FACS-sorted CD45RA
or CD45RO T cells were activated by plate-bound anti- (Figure 6D). However, both CD45RA and CD45RO T cells
could respond to IL-12 under these conditions. These re-CD3 antibodies and soluble anti-CD28 mAbs in the ab-
sence or presence of Hy-p40-p19, IL-12, or IL-2. Acti- sults indicate that Hy-p40-p19 acts on human CD45RO
Immunity
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Figure 6. p19p40 Stimulates the IFN-g Pro-
duction and the Proliferation of Human PHA
Blasts and Activated/Memory T Cells
(A) PHA blasts were derived from cultured
PBMC in PHA (0.1 mg/ml)- and IL-2 (10 U/mL)-
containing medium. After 7 days, cells were
stimulated for 60 hr with 40 ng/ml hHy-p40-
p19 or 1 ng/ml IL-12 and 1 mg/ml soluble anti-
CD28 in 96-well plates coated with 10 mg/
ml anti-CD3 mAb. IFN-g was measured by
ELISA.
(B) Remaining cells were then pulsed with
1 mCi/well 3H-thymidine (NEN) for 6 hr, and
incorporation of 3H-thymidine was deter-
mined by scintillation counting. All blocking
antibodies and isotype controls were used at
10 mg/ml.
(C and D) p19p40 has a more pronounced
effect on human CD45RO (memory) than on
CD45RA (naive) T cells. FACS-purified
CD45RA and CD45RO T cells were cultured
on anti-CD3 (10 mg/ml) and anti-CD28 (1 mg/ml) coated 96-well plates and stimulated with 40 ng/ml hHy-p19-p40, 1 ng/ml IL-12 (R&D Systems),
or 100 U/ml IL-2 (R&D Systems) for 60 or 136 hr. IFN-g production (C) and proliferation (D) were determined as in (A) and (B).
memory T cells and on CD45RA naive T cells but on cytokine is also similar to IL-12p35 in other ways: (1) p19
cosecretes with the p40 subunit of IL-12; (2) formation ofthe latter population only after a prolonged activation
period. biologically active p19p40 heterodimer requires synthe-
sis of both subunits within the same cell; (3) the p19p40
interaction is stabilized by an interchain disulfide bond;Hy-p40-p19 Binds to IL-12Rb1 but Not to IL-12Rb2
To investigate the molecular basis of the effects de- and (4) p19p40 binds to IL-12Rb1, the p40-specific com-
ponent of IL-12R (Presky et al., 1996a). p19p40 differsscribed above, we analyzed the signaling receptors
used by p19p40. Ba/F3 cells were infected with retroviral from p35p40 in requiring an as yet unidentified trans-
membrane receptor subunit to complete the p19p40constructs encoding human or mouse forms of IL-12Rb1
or -b2 (Gubler and Presky, 1996; Wu et al., 1996) (Figure signaling receptor complex. The identification of a re-
ceptor common to both signaling complexes provides7). Ba/F3 cells expressing hIL-12Rb1 bound human Hy-
p40-p19 and hIL-12 (Figure 7A). Binding of mouse Hy- a molecular rationale for our finding that p19p40 shows
both overlapping and unique functions in comparisonp40-p19 could be detected only on cells expressing
the IL-12Rb1 but not on cells expressing the IL-12Rb2 with IL-12. The interleukin designation for p19p40 is
interleukin-23.(Figures 7B and 7C). Ba/F3 cells tranfected with both
receptor subunits proliferated in response to IL-12 but IL-12 p35p40 is mainly produced by monocytes, mac-
rophages, and other antigen-presenting cells. Similarly,not upon addition of Hy-p40-p19 stimulation (Figure 7D).
Taken together, our data show that p19p40 and IL-12 p19p40 is produced by activated human and mouse
dendritic cells. In fact, in the supernatant of activatedshare IL-12Rb1 but not IL-12Rb2 in their respective sig-
naling complexes. human dendritic cells we find evidence for the simulta-
neous production of both IL-12 and p19p40 heterodi-
mers (Figures 4C and 4D). Although p19 mRNA is ex-Hy-p40-19 Activates Stat4
IL-12 stimulation results in the activation of Stat4 (Bacon pressed in endothelial cells and polarized T cells, p40
is not found in these cells. The availability of functionalet al., 1995; Jacobson et al., 1995). IL-12Rb2 has been
identified as the subunit that links IL-12 signaling to IL-12 is also limited by the expression of p40 and not
by p35, which is expressed in most cell types at lowStat4 activation (Naeger et al., 1999). Since p19p40 does
not share this receptor with IL-12 but presumably uses levels (D’Andrea et al., 1992). This suggests that func-
tional expression of both composite factors is regulatedits own unique receptor subunit in addition to IL-12Rb1,
we asked whether p19p40 can activate Stat4. Hy-p40- in a similar fashion. p19 has no N-glycosylation sites.
In contrast, p35 is extensively posttranslationally modi-p19 significantly induced the activation of Stat4 in hu-
man PHA blast T cells (Figure 7E). The level of activation fied by N-linked glycosylation. Recent studies show that
these modifications of p35 are a required step in thewas always less than that observed with IL-12 stimula-
tion, which is in agreement with the lower levels of IFN-g secretion of the p35p40 complex (Carra et al., 2000).
Secretion of p40 does not require such modifications.induced by p19p40 in these cells. This result suggests
that p19p40 is linked to the Stat4 signaling pathway. The Since secretion of neither p40 nor p19 depends on the
addition of N-linked oligosaccharides, it is possible thatidentification of a specific p19p40 receptor is currently
under investigation. upon activation of antigen-presenting cells capable of
producing both factors p19p40 is produced at earlier
times.Discussion
Our initial attempts to detect a biological activity for
p19 by itself failed. Partially purified mouse p19 had noWe describe a novel four–a helix cytokine called p19
that is most closely related in structure to IL-12p35. This biological activity on its own when tested in the same
Novel Composite Factor p19p40 Is Related to IL-12
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etic cells from the bone marrow produce biologically
active p19. Together, these experiments indicate that
p19, either administered as protein or expressed via
mRNA on its own, is not sufficient to elicit a biological
response.
In characterizing the biological activity of p19p40, we
initially compared it to IL-12. IL-12 is a cofactor that
synergizes with IL-2 to enhance the proliferation, cyto-
toxicity, and production of cytokines, in particular IFN-g,
by T cells and NK cells (Trinchieri, 1995; Gately et al.,
1998). Furthermore, IL-12 induces the differentiation of
naive T cells into Th1 cells (Hsieh et al., 1993; Manetti
et al., 1993). Like IL-12, p19p40 enhanced proliferation
and production of IFN-g by activated human PHA blast
T cells. The maximum levels of IFN-g production induced
by p19p40 were always lower than those induced by IL-
12, even at saturating levels of the added cytokines.
This characteristic may make p19p40 a more suitable
entity to stimulate the cell-mediated immune response
in cancer patients, as IL-12 administration leads to se-
vere cytotoxicity associated with extremely high IFN-g
levels in the serum of such patients (Leonard et al.,
1997). The immunoregulatory effects of p19p40 were
also examined on CD41 naive and memory T cell subsets
in both mice and human. In mice, p19p40 did not en-
hance proliferation of IL-12-responsive naive CD45RB
high cells. Similar observations were made on human
CD45RA naive T cells. However, CD45RA T cells could
Figure 7. The p19p40 Complex Binds to IL-12Rb1 but Not to IL- respond to p19p40 by increasing production of IFN-g
12Rb2 and Activates Stat4 after prolonged stimulation. This might be explained if,
Cells were infected with retroviral supernatants for 24–48 hr and like IL-12Rb2, the p19p40- specific receptor subunit is
then incubated with cytokines. Bound Hy-p40-p19 was detected not present on freshly isolated naive T cells but is in-
using an anti-Flag mAb, bound IL-12 with anti-p40 mAb.
duced following TCR triggering. In contrast, both mouse(A) Ba/F3 cells expressing hIL-12Rb1 bind human Hy-p40-p19. Con-
and human memory T cells respond strongly to p19p40trols, no antibody and secondary antibody only; hIL-12, 1 mg/ml;
by enhanced proliferation and, in the case of humanhHy-p40-p19, 1 mg/ml.
(B and C) Ba/F3 cells expressing mIL-12Rb1 but not mIL-12Rb2 cells, by enhanced IFN-g production. Interestingly, hu-
bind mouse Hy-p40-p19. (B) Controls, Ba/F3-mIL-12Rb1, no anti- man memory T cells but not mouse memory T cells were
body and secondary antibody only; Ba/F3-mIL-12Rb1, 1 mg/ml also very responsive to IL-12. This may represent a true
mouse Hy-p40-p19. (C) Control, Ba/F3-mIL-12Rb2, secondary anti- species difference or more likely indicates that the sub-
body only; mIL-12, 1 mg/ml; mouse Hy-p40-p19, 1 mg/ml.
populations of T cells as defined by these CD45 isoforms(D) Ba/F3 cells expressing mIL-12Rb1 and b2 respond to IL-12 but
are not equivalent.not Hy-p40-p19. Cells were stimulated with varying cytokine con-
IL-12 plays an important role in promoting cell-medi-centrations, and proliferation was measured as metabolic activity
visualized by the reduction of a colorimetric REDOX indicator. ated immunity against microbial pathogens. Endoge-
(Closed circles) and (closed squares), stimulation of Ba/F3-IL- nous IL-12 is essential for the host defense against My-
12Rb1b2 with mIL-12 or mHy-p40-p19, respectively. cobacterium tuberculosis, Leishmania major, Listeria
(E) Hy-p40-p19 induces phosphorylation of Stat4. Day 3 PHA blasts monocytogenes, and Klebsiella pneumoniae, as deter-
were incubated with medium, Hy-p40-p19 (1 mg), IL-12 (50 ng), or
mined by neutralization with blocking anti-IL-12 p40 an-IL-2 (1000 U) for 20 min and lysed. Stat4 immunoprecipitates were
tibodies (Tripp et al., 1994; Greenberger et al., 1996;run on denaturing gels, transferred and blotted with anti-phospho-
Cooper et al., 1997; Mattner et al., 1997). However, thesetyrosine mAb 4G10, and stripped and reblotted with anti-Stat4 mAb.
same antibodies, as shown here, also block the activity
of p19p40. Thus, studies using anti-p40 antibodies ad-
in vitro assays that later identified p19p40 as the active dress the role of both IL-12 and p19p40. Analyses of IL-
complex (data not shown). Additionally, administration 12p35- and IL-12p40-deficient mice have shown that
of p19 adenovirus to mice did not reveal a biological p35-deficient mice are less susceptible to L. monocyto-
response. Similarly, transgenic mice expressing mouse genes infection than p40-deficient mice (Brombacher
p19 under the control of a liver-specific promoter et al., 1999); in addition, IL-12 p40-deficient mice died
showed no obvious abnormalities (M. Wiekowski, un- earlier and developed higher organ burdens following
published data). In contrast, transgenic mice expressing infection by Cryptococcus neoformans than p35-defi-
mouse p19 mRNA in multiple tissues display a striking cient mice (Decken et al., 1998). Since p35-deficient
phenotype characterized by runting, systemic inflamma- mice are unable to produce IL-12 but should still be
tion, infertility, and premature death (M. Wiekowski et capable of making p19p40, this observation suggests
al., unpublished data). Moreover, this phenotype can that p19p40 can contribute to clearance of Listeria and
be transferred to irradiated mice transplanted with p19 Cryptococcus and argues for a protective role of p19p40
in bacterial infection. Similarly, the phenotype of IL-transgenic bone marrow cells indicating that hematopoi-
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was profile aligned to other sequences (including distant species12Rb1-deficient mice is more severe than that of IL-
variants of the aforementioned cytokines, plus CT-1, GPA, and viral12Rb2-deficient mice (Wu et al., 1997, 2000). In particu-
IL-6’s) with Clustal X (Thompson et al., 1997)—with some manuallar, IL-12Rb1 animals are more severely impaired in their
adjustment. A weighted profile (Thompson et al., 1994) of the most
ability to produce IFN-g following endotoxin administra- conserved region of the fold, the C-terminal D helix segment, an
tion in vivo and following ConA or anti-CD3 activation z40 amino acid block, was created. Fast scans of sequence data-
bases on a Bioccelerator machine (Compugen, Tel Aviv, Israel) withof splenocytes in vitro. Together, these results indicate
the Profilesearch program (Gribskov et al., 1987) identified two IM-that elimination of both IL-12 and p19p40 pathways re-
AGE ESTs (AA18955 and AA418747) that were used for the computa-sults in a more severe disturbance of the immune system
tional reconstruction of the human p19 sequence, and the cloningthan loss of only IL-12 signaling.
of its full-length cDNA.
Although IL-12 plays a key role in the generation of
protective immunity, it has also been implicated in the
Identification of Mouse p19immunopathology of organ-specific autoimmune dis-
Based on a strong cross-species hybridization signal, pools of a
eases in humans such as diabetes, arthritis, and Crohn’s RAW library (activated monocyte cell line) were generated and
disease. Direct evidence that IL-12 plays a major role screened with a human p19 probe. The full-length 1353 bp cDNA
in generating Th1-mediated diseases has been provided encodes a 189 aa protein. Both human and mouse p19 cDNA se-
quences have been deposited at GenBank (accession numbersby rodent studies in which treatment with a neutralizing
AF301619 and AF301620). Identical sequences were deposited byanti-IL-12 mAb prevents the onset of diseases such as
Y. Hirata and Y. Kosuge (accession numbers NM_016585 andcollagen-induced arthritis (Adorini et al., 1997), experi-
AB030001).
mental autoimmune encephalomyelitis (EAE) (Leonard
et al., 1995), and chronic IBD (Blumberg et al., 1999).
Transient Transfection, Metabolic Labeling,Because antibodies used in these studies block the
and Immunoprecipitation
function of both IL-12 and p19p40, these studies do Cells (1 3 106) were transiently transfected with 5 mg empty vector
not address the role of each individual factor in these or expression vectors encoding human or mouse forms of p19-
diseases. Support for a unique role of p19p40 in chronic N-Flag, IL-12p40, or both. Cells were cultured for 24 hr and then
metabolically labeled for 16 hr with 50 mCi/ml Pro-mix L-[35S] in vitroinflammation comes from our observation that p19p40
cell labeling mix (Amersham Pharmacia) in cysteine/methionine freehas a much more pronounced effect on the proliferation
MEM. Proteins were precipitated from 300 ml supernatant with eitherof memory T cells isolated from IL-10-deficient mice with
the anti-Flag M2 agarose (Sigma), anti-hp40/p70 antibody C8.6
inflammatory bowel disease as compared to memory T (Pharmingen), or anti-mp40/p70 C17.8 (Genzyme) bound to protein
cells from wild-type mice or normal human donors. Thus, G sepharose (Amersham Pharmacia).
the greatly increased number of Th1 memory/activated
cells present in chronically inflamed intestines and 2D-PAGE
draining lymph nodes of IL-10-deficient mice may reflect For nonreducing/reducing PAGE, purified p19p40 heterodimer was
their selective expansion in response to p19p40 (David- run in two lanes of a nonreducing 10% NuPage gel in MES running
buffer (Novex). The lanes were excised, reduced in sample bufferson et al., 2000). The predominance of Th1 cells with a
containing DTT, laid horizontally on two-well 10% gels, and runmemory/activated phenotype has also been observed
reduced in a second dimension. One gel was silver stained (Daiichi)in chronic lesions of rodents with various forms of auto-
while the other was blotted to a PVDF membrane and developed
immune disease (TNB-induced colitis, EAE, and colla- using the mouse p19-specific rat mAb 19A11 (1 mg/ml) and the
gen-induced arthritis). Whether p19p40 plays a critical HRP-coupled sheep anti-rat Ig NA932 (Amersham). For isoelectric
role in the maintenance and or function of these T cells focusing, immunoprecipitated 35S-labeled heterodimer was run on
pH 3–10 immobiline drystrips (Amersham Pharmacia) followed byremains to be determined. Thus, studies are in progress
SDS-PAGE and autoradiography.to establish the importance of p19p40 as a mediator of
immunological disease and conversely, as a costimula-
Quantitation of mRNA Expressiontor of protective immune responses.
cDNAs from various libraries or cultured macrophages and dendriticThe discovery of p19p40 as a novel composite factor
cells were prepared as described (Bolin et al., 1997) and used asclosely related to IL-12 in structure and with biological
templates for quantitative PCR. Fifty nanograms cDNA was analyzedactivities similar as well as distinct from IL-12 raises
for expression of p19, IL-12p35, or IL-12p40 by the fluorogenic
important issues. The anti-p40 antibodies used in critical 59-nuclease PCR assay (Holland et al., 1991) using the ABI Prism
studies to address the role of IL-12 in immunity and 7700 Sequence Detection System (Perkin-Elmer). Primers and
probes for human and mouse IL-12p35 and IL-12p40 were obtainedimmunopathology do not discriminate between IL-12
as Taqman PDAR’s (Perkin-Elmer, Foster City, CA). Analysis of cDNAand p19p40. From the work presented here, as well as
samples from cultured cells was corrected for expression of 18Sfrom studies based on mice deficient in either shared
rRNA using a VIC-labeled probe (Perkin-Elmer, Foster City, CA) inor unique IL-12 and p19p40 pathway components, evi-
multiplex reactions.
dence is emerging that the biological functions of
p19p40 and IL-12 are intimately related. We are currently
Expression of mp19 IgG and E Tag Fusion Proteinsfocusing on the development of reagents to discriminate
A HindIII-XhoI fragment encoding the mp19 protein was inserted
between the biological functions of p19p40 and IL-12 into a modified form of pCDM8 encoding a C-terminal hIgG fusion
and their specific contributions to immunity and immu- protein. A vector encoding E Tag fusion protein was similarly con-
structed using pCDM8 (Pharmacia). Proteins were produced vianopathology.
transient transfection of COP5 or 293 cells followed by affinity chro-
matography purification via Protein A or Anti-E Tag. The Etag fusionExperimental Procedures
protein was blotted onto an PVDF membrane (0.2 mm, Biorad, Her-
cules, CA) and subjected to Edman degradation. The derived se-Identification of Human p19
A structural alignment of available IL-6 family cytokine folds (CNTF, quence was L-A-V-P-R-S-S-S-P-D, indicating that the mature N-ter-
minal mp19 residue is L20.LIF, IL-6, OSM, and GCSF) from FSSP (Holm and Sander, 1998)
Novel Composite Factor p19p40 Is Related to IL-12
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Development of Rat Anti-Mouse p19 Monoclonal Antibodies tive selection using Dynabeads M-450 (by Dynal A.S., Oslo. Norway).
Purified monocyte populations (85%–90% CD141) were cultured inRat anti-mouse p19 monoclonal antibodies (mAbs) were produced
from splenocytes of a female 8-week-old Lewis rat (Harlan Sprague GM-CSF (800 U/ml) and IL-4 (300 U/ml) (Schering-Plough, Kenil-
worth, NJ) at 5 3 105 cells/ml in RPMI 1 10% FBS for 6 days, withDawley, Indianapolis, IN) immunized with mouse p19:Ig fusion pro-
tein. The rat was primed with 50 mg of fusion protein in Complete a change of medium at day 3. At day 6, dendritic cells were induced
to mature by coculture with irradiated (7000 rad) CD40 ligand trans-Freund’s Adjuvant and boosted three times. Splenocytes were fused
with the mouse myeloma P3X63-AG8.653 using PEG 1500 (Boeh- fected L cells, LPS (1 mg/ml), IFN-g (100 U/ml), TNFa (100 U/ml)
(R&D Systems), or combinations of these.ringer-Mannheim). Hybridoma supernatants were screened in indi-
rect ELISA on PVC plates coated with 50 ml of 0.5 mg/ml p19:Etag
fusion protein. Selected positive hybridoma lines were subcloned,
PHA Blast Generation and Activationgrown in serum-free medium supplemented with SITE (Sigma), and
PHA blasts were derived by culture of PBMC in Yssel’s mediumpurified.
with 0.1 mg/ml PHA (Wellcome) at 106 cells/ml. Cells were plated at
a density of 2 3 104 cells per well with or without 40 ng/ml hHy-Purification of Natural Mouse and Human p19p40 Heterodimers
p19-p40 or 1 ng/ml huIL-12 on a 96-well plate coated with 10 mg/Dendritic cell supernatants and control medium were concentrated
ml anti-CD3 and 1 mg/mL soluble anti-CD28. After 60 hr, IFN-gto 453 using Centriprep 10 concentrators (Millipore). Immunopre-
production was determined by ELISA. Cells were then pulsed withcipitations of recombinant and natural human p19p40 heterodimers
1 mCi/well with 3H-thymidine (NEN) for 6 hr, harvested, and incorpo-were performed using goat-anti-mouse Ig beads preloaded with the
ration of 3H-thymidine determined. In blocking experiments, the fol-mouse anti-hp40/p70 antibody C8.6 (Pharmingen), while isotype-
lowing antibodies were used: polyclonal goat anti-human IL12Rb1control beads contained mouse IgG1 349,040 (Beckton-Dickinson).
(R&D cat#AF839), mouse anti-human p40/p70 C8.6 (PharmingenMouse p19p40 heterodimers and fusion protein were detected in
cat#20510D), mouse anti-human p35 (DIACLONE cat#855.120.010),solution using a sandwich ELISA in which plates were coated with
mouse anti-human p40 (Pharmingen cat#20711D), polyclonal goatthe p19-specific monoclonal antibody 20C10, and detection was
Ig (Jackson Immuno Research code 0055-000-003), and monoclonalperformed with the biotinylated p40-specific monoclonal antibody
mouse IgG1 (Pharmingen cat#20800D) as isotype controls at 10 mg/18482D (Pharmingen) and HRP-streptavidin 016-030-084 (Jackson).
ml. Western blots were performed following immunoprecipitation ofMouse p19 Western blots were performed with the rat-anti-p19
PHA blast lysates with anti-stat4 mAb (UBI cat # 06-788) and blottingmonoclonal antibody 19A11.
with anti-phosphotyrosine mAb 4G10 (UBI cat # 05-321) or reblotting
with anti-stat4.Recombinant Adenovirus and Protein Production
m19 cDNA and mIL-12p40 cDNA were inserted separately into the
transfer vector pQB1-AdCMV5-GFP (Quantum Biotechnologies,
CD45RA/CD45RO T Cell Proliferation and IFN-g ProductionMontreal, Canada) by PCR. Recombinant adenovirus was produced
FACS-purified CD45RA and CD45RO T cells (purity . 99%) wereas described in Quantum applications manual 24AL98. Recombinant
cultured at a density of 4 3 104 cells/well in a 96-well plate previouslyvirus (moi 100 mp19 virus plus moi 1000 mp40 virus) were used to
coated with anti-CD3 antibody at 10 mg/ml and soluble anti-CD28infect 5 3 108 cells in 1 L CMF-1 with culture in a Nunc Cell Factory
at 1 mg/ml with or without 40 ng/mL hHy-p40-p19, 1 ng/mL hIL-12(Nalge Nunc, Naperville, IL) for 3 days. The culture medium was
(R&D Systems), or 100 U/ml hIL-2 (R&D Systems). Anti-hIL-2 mAbclarified by centrifugation and filtered prior to application to a 1
17H12 and anti-hIL-2R Mab B-B10 (Diaclone) were added at 10 mg/ml NHS-activated HiTrap (Pharmacia, Uppsala, Sweden) column
ml where indicated. Cells were incubated for 60 or 136 hr, and 100coupled to 1 mg of mAb 20C10. The column was washed with
ml aliquots were collected to determine IFN-g production by ELISA.PBS and eluted with 100 mM glycine (pH 3.0), and the eluate was
Proliferation was measured as described for PHA blasts.immediately loaded onto a 4.6 3 100 mm Poros R2/H column (Per-
Septive Biosystems, Cambridge, MA) with elution via a 80 ml linear
gradient from 20% to 50% acetonitrile/0.1% trifluoroacetic acid.
FACS Analysis and Proliferation Assay
Human IL-12Rb1 cDNA (kindly provided by Dr. Xiaojing Ma) was
Expression of Human and Mouse Hy-p40-p19 cloned in the retroviral vector pMX (Kitamura, 1998). Ba/F3 cells
HindIII-NotI fragments were generated encoding the mature coding were infected with retroviral supernatants for 24–48 hr on petri
sequence of either human or mouse IL-12p40, followed by the syn- dishes coated with 30 mg/ml recombinant fibronectin fragments
thetic linker GSGSSRGGSGSGGSGGGGSKL and by the mature (Retronectin, TaKaRa). Expression of hIL-12Rb1 was detected using
coding sequence of either human or mouse p19. Fragments were goat anti-hIL-12Rb1 (R&D Systems) followed by phycoerythrin (PE)-
inserted into pFLAG-CMV-1 (Sigma). Proteins were produced via conjugated donkey anti-goat IgG (Jackson Immunoresearch).
transient transfection of 293 cells followed by affinity chromatogra- Mouse IL-12Rb1 and IL-12Rb2 cDNAs in pMX-IRES-EGFP were
phy purification via anti-FLAG M2-agarose (Sigma). provided by A. O’Garra and L. Showe (Showe et al., 1996; Heath
et al., 2000). Cells expressing both receptors were prepared by
Mouse T Cell Proliferation Assay coinfection with both retroviruses. Hy-p40p19 and IL-12 binding was
CD41CD45RBhigh or CD41CD45RBlow T cell subsets were purified assessed by FACS. Cells were incubated with 0–10 mg/ml (0–168 nM)
from the spleen and mesenteric lymph nodes of .6- month-old IL- Hy-p40p19 or 0–1 mg/ml IL-12 for 30 min on ice, followed by a single
102/2 C57/B6 N12 mice as described (Davidson et al., 1998). Cells wash. Bound Hy-p40p19 was detected using 10 mg/ml anti-FLAG M2
were fractionated into CD41CD45RBhigh and CD41CD45RBlow cell mAb (Sigma) followed by PE-conjugated anti-mouse IgG (Jackson
populations by two-color sorting on a FACSTAR plus (Beckton Immunoresearch), or biotinylated M2 (Sigma) followed by streptavi-
Dickinson). All populations were .99% pure upon reanalysis. din-PE (Pharmingen). Results were similar using the two procedures.
CD41CD45RBhigh or CD41CD45RBlow were put into a proliferation Human IL-12 binding was detected using anti-IL-12p40 mAb C11.5
assay with plate-bound anti-CD3 (145.2C11) stimulation as de- (Pharmingen) followed by PE-conjugated goat anti-mouse IgG.
scribed (Davidson et al., 1998). Additions to the growth media in- Mouse IL-12 binding was detected using rat anti-mIL-12 (p40) mAb
cluded anti-IL-2 mAb (JES6-1A12) 100 mg/ml, anti-IL-12(p40) mAb C17.15 (R&D Systems) followed by goat anti-rat IgG-PE (Jackson
(C.17.8), 250 mg/ml, IL-12 (R&D), purified recombinant Hy-p40-p19, Immunoresearch). Proliferation responses were measured as de-
293T cell supernatant containing mouse p19p40 heterodimer or scribed (Ho et al., 1993).
mock supernatant. Cells were incubated for 5 days in a humidified
chamber (378C, 5% CO2) with [3H]TdR (Amersham) added at a final
concentration of 1 mCi/well for the last 24 hr of incubation. Acknowledgments
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